You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Refanalin for Liver Transplantation
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Orthotopic liver transplantation is the most effective treatment for patients with end-stage liver disease. Ischemia-reperfusion injury associated with the retrieval, storage and transplantation of livers is a major
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Hepatic Growth Factor Mimetic for Liver Fibrosis
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Hepatic fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstr
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Kidney Preservation for Transplantation
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Renal transplantation is the most effective and cost efficient treatment for patients with established renal disease. However ischemia-reperfusion injury associated with the retrieval, storage and transplantation of ki
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Potential of Refanalin in Pulmonary Fibrosis
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a devastating disease with less than a 50% five-year survival. While steroids and other immunosuppressive agents serve as the standard treatment for IPF, these agents have pro
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Protection from Stroke by SF/HGF-like Small Molecule
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Atherosclerosis of the cerebral vasculature can produce occlusion and cerebral infarction. Although the tissue in the ischemia core dies within minutes, the surrounding tissue, termed the ischemic penumbra, sustain
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Head-Mounted Display for Medical Diagnostics (HMD-MD)
SBC: APPLIED SCIENCE INNOVATIONS, INC Topic: N/ADESCRIPTION (provided by applicant): Proposed is a new stereoscopic, high resolution Head Mounted Display for Medical Diagnostics (HMD-MD). The main envisioned application of the proposed device is in endoscopes, where visual perception is the dominant
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Maximum Likelihood FRET Imaging
SBC: LICKENBROCK TECHNOLOGIES, INC. Topic: N/ADESCRIPTION (provided by applicant): Fluorescence resonance energy transfer (FRET) imaging is a microscope technique that uses a dye pair. It detects bonding of proteins, and in turn, is used to deduce many activities such as chromosome dynamics through
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
MS BASED ANTIBODY PROTEIN CHIP TECH
SBC: BIOMACHINES, INC. Topic: N/AN/A
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Anti-Selectin Blocker for Liver Ischemic Injury
SBC: BIOMEDICA MANAGEMENT CORP. Topic: N/ADESCRIPTION (provided by applicant): Our objective is to develop a new treatment that will prevent or decrease the tissue damage caused by neutrophil infiltration after ischemia/reperfusion (I/R), which occurs as the result of stroke, coronary isc
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
WILDLIFE ORAL VACCINE AGAINST B. BURGDORFERI
SBC: BIOPEPTIDES CORP Topic: N/ADESCRIPTION (provided by applicant): Lyme disease is a significant public health treat, it is the most prevalent vector borne infectious disease in the United States, and its geographical range is expanding. The white-footed mouse is the major natural r
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health